Bausch Health's Phase 3 RED-C Trials for Hepatic Encephalopathy Prevention Fail to Meet Primary Endpoint
核心洞察
Bausch Health announced that its global Phase 3 RED-C clinical program evaluating rifaximin SSD for hepatic encephalopathy (搜索) prevention in liver cirrhosis (搜索) patients failed to meet the primary endpoint.
The program consisted of two randomized, double-blind, placebo-controlled trials involving more than 1,000 patients across 398 sites in 17 countries.
Despite the failure, the treatment was found to be safe and well-tolerated, with the company reviewing the dataset for potential new development opportunities.
Bausch Health Companies Inc. announced disappointing results from its global Phase 3 RED-C clinical program, which failed to demonstrate efficacy in preventing hepatic encephalopathy (搜索) in adults with liver cirrhosis (搜索). The comprehensive study evaluated amorphous-rifaximin solid soluble dispersion (搜索) (SSD) for the primary prevention of hepatic encephalopathy (HE) in patients who had never experienced prior episodes of this serious complication.
Trial Design and Scope
The RED-C program represented one of the largest clinical investigations in this patient population, consisting of two global, randomized, double-blind, placebo-controlled Phase 3 trials. The studies enrolled more than 1,000 patients across 398 sites in 17 countries, specifically targeting adults with liver cirrhosis (搜索) who had no prior hepatic encephalopathy (搜索) episodes.
The clinical trials aimed to evaluate rifaximin SSD's ability to delay the first episode of hepatic encephalopathy (搜索) in this vulnerable patient population. While the treatment demonstrated a favorable safety profile and was well-tolerated throughout the study period, both trials failed to achieve their primary endpoint.
Clinical Significance and Unmet Need
The failure of these trials represents a significant setback for patients with liver cirrhosis (搜索), a condition that ranks as the ninth leading cause of death according to October 25, 2024 data from the Centers for Disease Control and Prevention. Cirrhosis serves as a major cause of end-stage liver disease (搜索) in the United States, with disease progression typically characterized by the development of hepatic encephalopathy (搜索), jaundice, clinically significant ascites, or variceal hemorrhage.
"We are disappointed in the results, as there is currently no approved treatment for these patients," said Thomas J. Appio, Chief Executive Officer of Bausch Health. "We are currently reviewing the full dataset to determine potential new development opportunities."
Company Response and Future Directions
Despite the negative results, Bausch Health expressed gratitude to the clinical trial participants and research teams who made the study possible. "We want to thank the patients, families, investigators, and research teams whose participation made this important clinical research possible," Appio stated.
The company indicated it remains committed to advancing treatments in hepatology and other therapeutic areas. Bausch Health is currently conducting a comprehensive review of the complete dataset to identify potential alternative development pathways or opportunities for the compound.
Impact on Hepatology Treatment Landscape
The failed trials highlight the ongoing challenge in developing effective preventive treatments for hepatic encephalopathy (搜索) in cirrhosis patients. The absence of approved therapies for primary prevention of hepatic encephalopathy represents a significant unmet medical need, leaving clinicians with limited options for managing patients at risk of developing this debilitating complication.
The comprehensive nature of the RED-C program, with its large patient population and global reach, provided robust data that will likely inform future research directions in this therapeutic area, despite the disappointing primary results.